ChemDiv, Inc.

54 articles about ChemDiv, Inc.

• ChemDiv Forges Strategic Partnership with The University of Texas Medical Branch (UTMB) to Expand Its High-throughput Screening Research Capabilities

  12/28/2023

  ChemDiv announces a strategic collaboration with the University of Texas Medical Branch to facilitate the expansion of its inventory and advance the institution's High-throughput Screening research programs.

• ChemDiv Welcomes Peter Dmitriev and David Stark to Business Development Team, Announces Headquarters Expansion

  10/26/2023

  ChemDiv is excited to announce the expansion of its Business Development Team with the addition of two seasoned professionals, Peter Dmitriev as Business Development Manager and David Stark as Senior Regional Director of Business Development.

• ChemDiv Establishes a Cutting-edge Biology Facility in Portugal

  8/16/2023

  ChemDiv Inc, a global leader in drug discovery and drug development solutions, shares the progress in the development of its cutting-edge biology facility at Biocant Park, Cantanhede, Portugal.

• ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection

  8/13/2020

  ChemDiv Inc., a fully integrated California-based CRO, announced the creation of a unique platform for development of drugs against coronavirus infection that would simplify and accelerate antiviral candidate selection.

• Insilico Medicine and ChemDiv form a strategic drug discovery service alliance

  10/16/2019

  Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions.

• ChemDiv Announces Expansion of Multi-Year Hit Identification Collaboration With Janssen

  1/23/2018

  ChemDiv announced at the 36th Annual J.P. Morgan Healthcare Conference the expansion of its hit identification collaboration with Janssen R&D and extending it into finding potent anti-infective drug candidates.

• ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration

  1/4/2018

  The overall goal of the collaboration is to leverage DZNE's advanced research capabilities with ChemDiv's commercial expertise to efficiently design and validate new therapeutic candidates for treatment of Alzheimer's and other neurodegenerative diseases.

• ChemDiv's Discovery Chemistry Platform to Help Advance Tri-Institutional Therapeutics Discovery Institute Programs ChemDiv logo

  11/6/2017

  This collaboration with ChemDiv is aimed at assisting Tri-I TDI investigators with developing therapies across multiple therapeutic areas.

• ChemDiv, Inc. Announces Multi-Year Hit Identification Collaboration With Janssen R&D

  1/31/2017

• ChemDiv, Inc. Release: Company Announces Key Milestones In Abbott Pharma Collaboration

  1/11/2017

• ChemDiv, Inc., Torrey Pines Investment And DZNE Announce Research Collaboration

  10/17/2016

• ChemDiv, Inc. Announces New Drug Discovery Collaboration Agreement With Cystic Fibrosis Foundation Therapeutics, Inc.

  5/31/2016

• ChemDiv, Inc. Announces Achievement Of A Development Milestone In A Drug Discovery Collaboration With Janssen Pharmaceutical

  1/12/2016

• ChemDiv, Inc. Receives Multiple Milestones in Major Drug Discovery Collaboration With Eli Lilly and Company

  12/19/2012

• Coare Biostechnology and ChemDiv, Inc. Establish Co-Marketing and Service Collaboration

  11/8/2012

• UCB, Inc. and ChemDiv Research Institute Conclude First Phase of Discovery Chemistry Collaboration

  6/13/2012

• ChemDiv, Inc. Enters Into Research and Collaboration Agreement With Janssen Pharmaceutica N.V. and Tibotec Pharmaceuticals Ltd

  12/20/2011

• Emerald BioStructures and ChemDiv, Inc. Establish Co-Marketing Collaboration

  3/28/2011

• ChemDiv, Inc. Opens the Unique Chemistry E-Commerce Store Offering the World's Largest Small Molecule Inventory

  1/12/2011

• Viriom Selects ChemDiv, Inc. to Develop HIV Program

  10/19/2009